Endothelial cells in physiology and in the pathophysiology of vascular disorders

Blood

Volumn 91, Issue 10, 1998, Pages 3527-3561

  Cines, Douglas B ^a   Pollak, Eleanor S ^b   Buck, Clayton A ^b   Loscalzo, Joseph ^b   Zimmerman, Guy A ^b   McEver, Rodger P ^b   Pober, Jordan S ^b   Wick, Timothy M ^b   Konkle, Barbara A ^b   Schwartz, Bradford S ^b   Barnathan, Elliot S ^b   McCrae, Keith R ^b   Hug, Bruce A ^b   Schmidt, Ann Marie ^b   Stern, David M ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; ENDOTHELIUM CELL; FIBRINOLYSIS; GENETIC REGULATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE;

ANIMALS; ARTERIOSCLEROSIS; BLOOD CELLS; BLOOD COAGULATION; CELL ADHESION; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; CELLS, CULTURED; ENDOTHELIAL GROWTH FACTORS; ENDOTHELINS; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; EXTRACELLULAR MATRIX; FEMALE; FIBRINOLYSIS; FIBROBLAST GROWTH FACTOR 2; HEMODYNAMIC PROCESSES; HUMANS; INFLAMMATION; LYMPHOKINES; MALE; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; PLATELET ACTIVATING FACTOR; PRE-ECLAMPSIA; PREGNANCY; THROMBOSIS; UMBILICAL VEINS; VASCULAR DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032525207     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (467)

1. Fishman AP: Endothelium: A distributed organ of diverse capabilities. Ann NY Acad Sci 401:1, 1982
2. Augustin HG, Kozian DH, Johnson RC: Differentiation of endothelial cells: Analysis of the constitutive and activated endothelial cell phenotypes. Bioessays 16:901, 1994
3. Jaffe EA, Nachman RL, Becker CG. Minick CR: Culture of human endothelial cells derived from umbilical veins: Identification by morphologic criteria. J Clin Invest 52:2745, 1973
4. Gimbrone MA, Cotran RS, Folkman J: Human vascular endothelial cells in culture. Growth and DNA synthesis. J Cell Biol 60:673, 1974
5. Lewis LJ, Hoak JC, Maca RD, Fry GL: Replication of human endothelial cells in culture. Science 181:453, 1973
6. Fishman MC, Stainier DYR: Cardiovascular development: Prospects for a genetic approach. Circ Res 74:757, 1994
7. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353, 1996
8. Risau W, Flamme I: Vasculogenesis. Annu Rev Cell Dev Biol 11:73, 1995
9. Palis J, McGrath KE, Kingsley PD: Initiation of hematopoiesis and vasculogenesis in murine yolk sac explants. Blood 86:156. 1995
10. Flamme I, Baranowski A, Risau W: A new model of vasculogenesis and angiogenesis in vitro as compared with vascular growth in the avian area vasculosa. Anat Rec 237:49, 1993
11. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T. Witzenbichler B, Schatteman G, Isner JM: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964, 1997
12. Risau W: Differentiation of endothelium. Endothelium Differ 9:926, 1995
13. Buck CA, Edelman JM, Buck CE, Kennedy G, Baldwin HS: Expression patterns of adhesion receptors in the developing mouse lung: Function implications. Cell Adhesion Commun 4:69, 1996
14. Pardanaud L, Yassine F, Dieterlen-Lievre F: Relatonship between vasculogenesis, angiogenesis and haemopoiesis during avian ontogeny. Development 105:473, 1989
15. Bielinska M, Narita N, Heikinheimo M, Porter SB, Wilson DB: Erythropoiesis and vasculogenesis in embryoid bodies lacking visceral yolk sac endoderm. Blood 88:3720, 1996
16. Beck L Jr, D'Amore P: Vascular development: Cellular and molecular regulation. FASEB J 11:365, 1997
17. Breier G, Risau W: The role of vascular endothelial growth factor in blood vessel formation. Trends Cell Biol 6:454, 1996
18. Shalaby R, Rossant J, Yamaguchi TP, Gertsenstein M, Wu X-F, Breitman ML, Schuh AC: Failure of blood-island formation and vasculogenesis in FLK-1-deficient mice. Nature 376:62, 1995
19. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y: Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376:70, 1995
20. Mustonen T, Alitalo K: Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 129:895, 1995
21. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87:1161, 1996
22. Maisonpierre P, Suri G, Jones P, Bartunkova S. Wiedgand S, Radziejewski C, Compton D, McClain J, Aldrich T, Papadonopoulos N, Daly T, Davis S, Sato T, Yankopoulos GD: Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science 277:55, 1997
23. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD: Requisite role of angiopoietin-1, a ligand for the Tie-2 receptor during embryonic angiogenesis. Cell 87:1171, 1996
24. Folkman J, D'Amore PA: Blood vessel formation: What is the molecular basis? Cell 87:1153, 1996
25. Vikkula M, Boou L, Carraway K, Calvert J, Diamond A, Gooumnerov B, Pasyk K, Marchuk D, Warman M, Cantley L, Mulliken J, Olsen BR: Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase. Cell 87:1181, 1996
26. Stainier DYR, Fishman MC: The zebrafish as a model system to study cardiovascular development. Trends Cardiovasc Med 4:207, 1994
27. Sankar S, Mahooti-Brooks N, Bensen L, McCarthy TL, Centrella M, Madri JA: Modulation of transforming growth factor β receptor levels on microvascular endothelial cells during in vitro angiogenesis. J Clin Invest 97:1436, 1996
28. Schwartz MA, Schaller MD, Ginsburg MH: Integrins: emerging paradigms of signal transduction. Annu Rev Cell Develop Biol 11:549, 1995
29. Varner JA, Brooks PC, Cheresh DA: Review: The integrin ανβ3: Angiogenesis and apoptosis. Cell Adhesion Commun 3:367,1995
30. Hynes RO: Targeted mutations in cell adhesion genes: What have we learned from them? Dev Biol 180:402, 1996
31. Albelda SM, Muller WA, Buck CA, Newman PJ: Molecular and cellular properties of PECAM-1 (endoCAM/CD31 ): A novel vascular cell-cell adhesion molecule. J Cell Biol 114:1059, 1991
32. Dejana E: Endothelial adherens junctions: Implications in the control of vascular permeability and angiogenesis. J Clin Invest 98:1949, 1996
33. Bretscher MS: Moving membrane up to the front of migrating cells. Cell 85:465, 1996
34. Carmeliet P, Collen D: Gene targeting and gene transfer studies of the plasminogen/plasmin system: Implications in thrombosis, hemostasis, neointima formation, and atherosclerosis. FASEB J 9:934, 1995
35. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL: The cell biology of the plasmmogen system. FASEB J 9:939, 1995
36. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthan RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315, 1994
37. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277, 1997
38. Zetter BR: On target with tumor blood vessels. Nat Biotechnol 15:1243, 1997
39. McCarthy SA, Kuzu I, Gatter KC, Bicknell R: Heterogeneity of the endothelial cell and its role in organ preference of tumour metastasis. TIPS 12:462, 1991
40. Kumar S, West DC, Ager A: Heterogeneity in endothelial cells from large vessels and microvessels. Differentiation 36:57, 1987
41. Turner RR, Beckstead JH, Warnke RA, Wood GA: Endothelial cell phenotypic diversity. In situ demonstration of immunologic and enzymatic heterogeneity that correlates with specific morphologic subtypes. Am J Clin Pathol 87:569, 1985
42. Levin EG, Osborn KG: The expression of endothelial cell tissue plasminogen activator in vivo: A function defined by vessel size and anatomic location. J Cell Sci 11:139, 1997
43. Wojta J, Hoover RL, Daniel TO: Vascular origin determines plaminogen activator expression in human endothelial cells. Renal endothelial cells produce large amounts of single chain urokinase type plasminogen activator. J Biol Chem 264:2846, 1989
44. Louise CB, Obrig TG: Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro. Microvase Res 47:377, 1994
45. Obrig TG, Louise CB, Lingwood CA, Boyd B, Daniel TO: Endothelial cell heterogeneity in shiga toxin receptors and responses. J Biol Chem 268:15484, 1993
46. Mitra D, Jaffe EA, Weksler B, Hajjar KA, Doserland C, Laurence J; Thrombotic thrombocytopenic purpura and sprodic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood 89:1224, 1997
47. Drake TA, Cheng J, Chang A, Taylor FB Jr: Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal, Eschericia coli sepsis. Am J Pathol 142:1458, 1993
48. Zhu D, Cheng C-F, Pauli BU: Mediation of lung metastasis of murine melanoma by a lung-specific endothelial cell adhesion molecule. Proc Natl Acad Sci USA 88:9568, 1991
49. Butcher EC, Picker LJ: Lymphocyte homing and homeostasis. Science 272:60, 1996
50. Rafii S, Shapiro F, Pettengall R, Ferris B, Nachman RL, Moore MA, Asch AS: Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocyte progenitors. Blood 86:3353, 1995
51. Owman C, Hardbeo JE: Functional heterogeneity of cerebrovascular endothelium. Brain Behav Evol 32:65, 1988
52. Grau GE, de Moreloose P, Bulla O, Lou J, Lei Z, Reber R, Mili N, Ricou B, Morel DR, Suter PM: Haemostatic properties of human pulmonary and cerebral microvascular endothelial cells. Thromb Haemost 77:585, 1997
53. Morin O, Patry P, Lafleur L: Heterogeneity of endothelial cells of adult rat liver as resolved by sedimentation velocity and flow cytometry. J Cell Physiol 119:327, 1984
54. Couveland A, Scoazec J-Y, Dauge M-C, Bringer A-F, Potet FGF: Structural and functional differentiation of sinusoidal endothelial cells during liver organogenesis in humans. Blood 87:4568, 1996
55. Milici AJ, Furie MB, Carley WW: The formation of fenestrations and channels by capillary endothelium in vitro. Proc Natl Acad Sci USA 82:6181, 1985
56. Pardanaud L, Altmann C, Kitos P, Dieterlen-Lievre F, Buck CA: Vasculogenesis in the early quail blastodisc as studied with a monoclonal antibody recognizing endothelial cells. Development 100:339, 1987
57. Grau GE, Mili N, Lou JN, Morel DR, Ricou B, Lucas R, Suter PM: Phenotypic and functional analysis of pulmonary microvascular endothelial cells from patients with acute respiratory distress syndrome. Lab Invest 74:761, 1996
58. Aird WC, Edelberg JM, Weiler-Guettler H, Simmons WW, Smith TW, Rosenberg RD: Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenviromnent. J Cell Biol 138:1117, 1997
59. Pauli BU, Lee C-L: Organ preference of metastasis. The role of organ-specifically modulated endothelial cells. Lab Invest 58:379, 1988
60. Subramanian VA, Hernandez Y, Tack-Goldman K, Grabowski EF, Weksler BB: Prostacyclin production by internal mammary artery as a factor in coronary artery bypass grafts. Surgery 100:376, 1986
61. Ades EW, Caudal FJ, Swerlick RA, George VG, Summers S, Bosse DC, Lawley TJ: HMEC-1: Establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 99:683, 1992
62. Grant DS, Tashiro K-I. Segui-Real B, Yamada Y, Martin GR, Kleinman HK: Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58:933, 1989
63. Gibbons GH, Dzau VJ: Molecular therapies for vascular diseases. Science 272:689, 1996
64. Stamler JS, Singel DJ, Loscalzo J: Biochemistry of nitric oxide and its redox-activated forms. Science 258:1898, 1992
65. Venema RC, Sayegh HS, Arnal JF, Harrison DG: Role of the enzyme calmodulin-binding domain in membrane association and phospholipid inhibition of endothelial nitric oxide synthase. J Biol Chem 270:14705, 1995
66. Topper JN, Cai J, Falb D, Gimbrone MA Jr: Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-3, manganese Superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 93:10417, 1996
67. Awolesi MA, Widmann MD, Sessa WC. Sumpio BE: Cyclic strain increases endothelial nitric oxide synthase activity. Surgery 116:439, 1994
68. Loscalzo J, Vita JA: Ischemia, hyperemia, exercise, and NO: Complex physiology and complex molecular adaptations. Circulation 90:2556, 1994
69. Venema RC, Nishida K, Alexander RW, Harrison DG, Murphy TJ: Organization of the bovine gene encoding the endothelial nitric oxide synthase. Biochem Biophys Acta 1218:413, 1994
70. Balligand JL, Ungureanu-Longroid D, Simmons WW, Kobzik L, Lowenstein CJ, Lamas S, Kelly RA, Smith TW, Michel T: Induction of nitric oxide synthase in rat cardiac microvascular endothelial cells by IL-beta and IFN-gamma. Am J Physiol 268:H1293, 1995
71. Loscalzo J, Welch G: Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 38:87, 1995
72. Mendelsohn ME, O'Neill S, George D, Loscalzo J: Inhibition of ribrinogen binding to human platelets by S-nitroso-N-acetylcysteine. J Biol Chem 265:19028, 1990
73. Radomski MW, Palmer RMJ, Moncada S: Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide, and prostacyclin in platelets. Br J Pharmacol 92:181, 1987
74. 1, and nitroglycerin. Circ Res 65:769, 1989
75. Michelson AD, Benoit SE, Furman, MI, Breckwoldt WL, Rohrer MJ, Barnard MR, Loscalzo J: Effects of endothelium-derived relaxing factor/nitric oxide on platelet surface glycoproteins. Am J Physiol 39:H1640, 1996
76. Pigazzi A, Folli F, Heydrich S, Loscalzo J: Nitric oxide inhibits thrombin-induced phosphoinositide 3-kinase activity in human platelets. Circulation (in press)
77. Kubes P, Suzuki M, Granger DN: Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 88:4651, 1991
78. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, Liao JK: Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 96:60, 1995
79. Marks DS, Vita JA, Foils JD, Keaney JF Jr, Welch GN, Loscalzo J: Inhibition of neointimal proliferation in rabbits following vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest 96:2630, 1995
80. Garg UC, Hassid A: Nitric oxide (NO) and 8-bromo-cyclic GMP inhibit mitogenesis and proliferation of cultured rat vascular smooth, muscle cells. J Clin Invest 83:1974, 1989
81. Fukuo K, Inoue T, Morimoto S, Nakahasi T, Yasuda O, Kitanno S, Sasanda A, Ogihara T: Nitric oxide mediates cytoxicity and basic fibroblast growth factor release in cultured vascular smooth muscle cells. J Clin Invest 95:669, 1995
82. Garland CJ, Plane F, Kemp BK, Cocks TM: Endothelium-dependent hyperpolarization: A role in the control of vascular tone. Trends Biol Sci 16:23, 1995
83. Feletou M, Vanhoutte PM: Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br J Pharmacol 93:515, 1988
84. Levin ER: Endothelins. N Engl J Med 333:356, 1996
85. Nakamura S, Naruse M, Maruse K, Demura H, Uemura H: Immunocytochemical localization of endothelin in cultured bovine endothelial cell. Histochemistry 94:475, 1990
86. Simonson MS, Dunn MJ: Cellular signaling by peptides of the endothelin gene family. FASEB J 4:2989, 1990
87. Goligorsky MS, Tsukahara H, Magazine H, Andersen TT, Malik AB, Bahou WF: Termination of endothelin signaling: Role of nitric oxide. J Cell Physiol 158:485, 1994
88. Lopez JA, Armstrong ML, Piegors DJ, Heistad DD: Vascular responses to endothelin-1 in atherosclerotic primates. Arteriosclerosis 10:1113, 1990
89. Zimmerman GA, Whatley RE, Benson DE, McIntyre TM, Prescott SM: Endothelial cells for studies of platelet-activating factor and arachidonate metabolites. Methods Enzymol 187:520, 1990
90. Meade EA, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM: Prostaglandins and related compounds. Lipid messengers with many actions. Handbook Lipid Res 8:285, 1996
91. Whatley RE, Zimmerman GA, Prescott SM, McIntyre TM: Platelet-activating factor and PAF-like mimetics. Handbook Lipid Res 8:239, 1996
92. Imaizumi T, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, Zimmerman GA: Platelet-activating factor: A mediator for clinicians. J Intern Med 238:5, 1995
93. Campbell WB, Halushka PV: Eicosanoids and platelet-activating factor, in Hardman JG, Limbird LE, Molinoff PM, Ruddon RW, Gilman AG (eds): Goodman and Gilman's The Pharmacologic Basis of Therapeutics. New York, NY, McGraw-Hill, 1996, p 601
94. Lorant DE, Zimmerman GA, McIntyre TM, Prescott SM: Platelet-activating factor mediates procoagulant activity on the surface of endothelial cells by promoting leukocyte adhesion. Semin Cell Biol 6:295, 1995
95. 2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci USA 74:3922, 1977
96. McIntyre TM, Zimmerman GA, Satoh K, Prescott SM: Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin and ATP. J Clin Invest 76:271, 1985
97. Coleman RA, Smith WL, Narumiya S: Classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46:205, 1994
98. Majerus PW: Arachidonate metabolism in vascular disorders. J Clin Invest 72:1521, 1983
99. FitzGerald GA, Pedersen AK, Patrono C: Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 67:1174, 1983
100. Chen X-S, Sheller JR, Johnson EN, Funk CD: Role of leukotrienes revealed by targeted distruption of the 5-lipoxygenase gene. Nature 372:179, 1992
101. Bombeli T, Meiler M, Haeberli A: Anticoaguant properties of the vascular endothelium. Thromb Haemost 77:408, 1997
102. Rosenberg RD, Rosenberg JS: Natural anticoagulant mechanisms. J Clin Invest 74:1, 1984
103. Bauer KA, Weiss LM, Sparrow D, Vakonas PS, Rosenberg RD: Aging-associated changes in indices of thrombin generation and protein C activation in human. Normative aging study. J Clin Invest 80:1527, 1987
104. Marcum JA, Rosenberg RD: Anticoagulantly active heparinlike molecules from vascular tissue. Biochemistry 23:1730, 1984
105. Tollefsen DM, Pestka CA: Heparin cofactor II activity in patients with disseminated intravascular coagulation and hepatic failure. Blood 66:769, 1985
106. Broze GJ Jr: Tissue factor pathway inhibitor. Thromb Haemost 74:90, 1995
107. Jesty J, Lorenz A, Rodriguez J, Wun T-C: Initiation of the tissue factor pathway of coagulation in the presence of heparin: Control by antithrombin III and tissue factor pathway inhibitor. Blood 87:2301, 1996
108. Bombeli T, Karsan A, Tait JF, Harlan JM: Apoptotic vascular endothelial cells become procoagulant. Blood 90:2429, 1997
109. Esmon CT, Fukudome K: Cellular regulation of the protein C pathway. Semin Cell Biol 6:259 1995
110. Fair DS, Marlar RA, Levin EG: Human endothelial cells synthesize protein S. Blood 67:1168, 1986
111. Fukudome K, Kurosawa S, Stearns-Kurosawa D-J, He X, Rezaie AR, Esmon CT: The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor. J Biol Chem 271:17491, 1996
112. Thompson EA, Salem HH: Inhibition by human thrombomodulin of factor Xa-mediated cleavage of prothrombin. J Clin Invest 78:13, 1986
113. Esmon CT: Molecular events that control the protein C anticoagulant pathway. Thromb Haemost 70:29, 1993
114. Nawroth PP, Stern DM: Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 163:740, 1986
115. Mantovani A, Sozzani S, Vecchi A, Introna M, Allavena P: Cytokine activation of endothelial cells: new molecules for an old paradigm. Thromb Haemost 78:406, 1997
116. Cucurull E, Gharavi AE: Thrombomodulin: A new frontier in lupus research? Clin Exp Rheumatol 15:1, 1997
117. Drake TA, Morrissey JH, Edgington TS: Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 134:1087, 1989
118. Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, van Vlaenderen I, Demunck H, Kaspar M, Breier G, Evrard P, Muller M, Risau W, Edginston T, Collen D: Role of tissue factor in embryonic blood vessel development. Nature 383:73, 1996
119. Bugge TH, Xiao Q, Kormbrinck KW, Flick MJ, Holmback K, Danton MJS, Colbert MC, Witte DP, Fujikawa K, Davie E, Degen JL: Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiation of blood coagulation. Proc Natl Acad Sci USA 93:6258, 1996
120. Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ Jr: Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 88:1583, 1996
121. Rapaport SI, Rao VM: The tissue factor pathway: How it has become a "Prima Ballerina". Thromb Haemost 74:7, 1995
122. Nemerson Y: Tissue factor: Then and now. Thromb Haemost 74:180, 1995
123. Ryan J, Brett J, Tijburg P, Bach RR, Kisiel W, Stern D: Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface. Blood 80:966, 1992
124. Narahara N, Enden T, Wiiger M, Prydz H: Polar expression of tissue factor in human umbilical vein endothelial cells. Arterioscler Thromb 14:1815, 1994
125. Bona R, Lee E, Rickles F: Tissue factor apoprotein: Intracellular transport and expression in shed membrane vesicles. Thromb Res 48:487, 1987
126. Shimura M, Wada H, Waskita Y, Nakse T, Hiyoyama K, Nagaya S, Shiku H: Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Pathol 52:165, 1996
127. Marmur JD, Rossikhina M, Guha A, Fyle B, Friedrich V, Mendlowitz M, Nemerson Y, Taubman MB: Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 91:2253, 1993
128. Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, Fallon JT: In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest 75:451, 1996
129. Hatakeyama K, Asada Y, Marutsuka K, Sato Y, Kamikubo Y, Sumiyoashi A: Localization and activity of tissue factor in human aortic atherosclerotic lesions. Atherosclerosis 133:213, 1997
130. Contrino J, Hair G, Kreutzer DL, Rickles FR: In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nat Med 2:209, 1996
131. Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Sumiyoshi A: Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost 75:389, 1996
132. Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP: Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 94:1320, 1994
133. Stern D, Nawroth P, Handley D, Kisiel W: An endothelial cell-dependent pathway of coagulation. Proc Natl Acad Sci USA 82:2523, 1985
134. Brinkman H-JM, Mertens K, Holthius J, Zwart-Huinink LA, Grijm K, van Mourik JA: The activation of blood coagulation factor X on the surface of endothelial cells: A comparison with various vascular cells, platelets and monocytes. Br J Haematol 87:332, 1994
135. Cheung WF, van den Born J, Kuhn K, Kjellen L, Hudson BG, Stafford DW: Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci USA 80:7001, 1996
136. Altieri DC: Xa receptor EPR-1. FASEB J 9:860, 1995
137. Bono F, Herault J-P, Avril C, Schaeffer P, Lormeau J-C, Herbert J-M: Human umbilical vein endothelial cells express high affinity receptors for factor Xa. J Cell Physiol 172:36, 1997
138. Etingen OR, Silverstein RL, Hajjar DP: Identification of a monocyte receptor on herpes-infected endothelial cells. Proc Natl Acad Sci USA 88:7200, 1991
139. Schmaier AH, Kuo A, Cines DB: High molecular weight kininogen expression on human endothelial cells. J Biol Chem 31: 16327, 1988
140. Woolkanis MJ, DeMelfi TM Jr, Blanchard N, Hoxie JA, Brass LF: Regulation of thrombin receptors on HUVECs. J Biol Chem 270:9686, 1995
141. Kanthou C, Benzakour O: Cellular effects of thrombin and their signalling pathways. Cell Pharmacol 2:293, 1995
142. Garcia JGN, Pavalko FM, Patterson CE: Vascular endothelial cell activation and permeability responses to thrombin. Blood Coag Fibrinol 6:609, 1995
143. Connolly AJ, Ishihara H, Kahn MI, Ferese RV Jr, Coughlin SR: Role of the thrombin receptor in development and evidence for a second receptor. Nature 381:516, 1996
144. Mirtza H, Yatsula V, Bahou WF: The proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cells. Molecular characterization and evidence for functional coupling to the thrombin receptor. J Clin Invest 97:1705, 1996
145. Ishihara H, Connoly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR: Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 386:502, 1997
146. Brass LF, Molino M: Protease-activated G protein-coupled receptors on human platelets and endothelial cells. Thromb Haemost 78:234, 1997
147. Odrijn TM, Francis CW, Sporn LA, Bunce LA, Marder VJ, Simpson-Haidaris PJ: Heparin-binding domain of fibrin mediates its binding to endothelial cells. Arterioscler Thromb Vase Biol 16:1544, 1996
148. Erban JK, Wagner DD: A 130-kDa protein on endothelial cells binds to amino acids 15-42 of the Bβ chain of fibrinogen. J Biol Chem 267:2451, 1992
149. Greenburg CS, Birckbichler PJ, Rice RH: Transglutaminases: Multifunctional cross-linking enzymes that stabilize tissues. FASEB J 5:3071, 1991
150. 3 is expressed in selected microvessels after focal cerebral ischemia. Am J Pathol 149:37, 1996
151. Ruosiahti E, Engvail E: Integrins and vascular extracellular matrix assembly. J Clin Invest 99:1149, 1997
152. Wagner DD, Bonfanti R: Von Willebrand factor and the endothelium. Mayo Clin Proc 66:621, 1991
153. Rajagopalan V, Essex DW, Shapiro SS, Konkle BA: Tumor necrosis factor-α odulation of glycoprotein Ibα expression in human endothelial and erythroleukemia cells. Blood 80:153, 1992
154. Beacham DA, Tran LP, Ludlow LB, Huang R, Konkle BA, Shapiro SS: Endothelial glycoprotein Ibα expression is upregulated by arterial shear stress. Blood 86:2188a, 1995 (abstr, suppl)
155. Taylor FB Jr: Studies on the inflammatory-coagulant axis in the baboon response to E. coli: Regulatory role of proteins C, S, C4bBP and of inhibitors of tissue factor. Prog Clin Biol Res 388:175, 1994
156. Hirsh J, Salzman EW, Marder VJ, Colman RW: Overview of the thrombotic process and its therapy, in Colman RW, Hirsh J, Marder VJ, Salzman EW (eds): Hemostasis and Thrombosis. Basic Principles and Clinical Pratice. Philadelphia, PA, Lippincott, 1994, p 1151
157. Todd AS: Histological localization of fibrinolysin activator. J Pathol Bacteriol 78:281, 1959
158. Pandolfi M: Histochemistry of tissue plasminogen activator. Thromb Diath Haemorrh 34:661, 1975
159. Levin EG, Marotti KR, Santell L: Protein kinase C and the stimulation of tissue plasminogen activator release from human endothelial cells. J Biol Chem 264:16030, 1989
160. Cugno M, Uziel L, Fabreizi I, Bottasso B, Maggiolini F, Agostoni A: Fibrinolytic response in normal subjects to venous occlusion and DDAVP infusion. Thromb Res 56:625, 1989
161. Levin EG, Santell L: Thrombin- and histamine-induced signal transduction in human endothelial cells. Stimulation and agonist-dependent desensitization of protein phosphorylation. J Biol Chem 266:174, 1991
162. McCrae KR, Aceto JF, Cines DB: Clinical aspects of the plasminogen activator system. Adv Pathol Lab Med 7:467, 1994
163. Bacharach E, Itin A, Keshet E: In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiologic angiogenesis. Proc Natl Acad Sci USA 89:10686, 1992
164. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degan J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 369:419, 1994
165. Yamamoto K, Loskutoff DJ: Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue type plasminogen activator. J Clin Invest 97:2440, 1996
166. Barnathan ES, Kuo A, van der Keyl H, McCrae KM, Cines DB: Binding of tissue type plasminogen activator to human endothelial cells: Evidence for two distinct binding sites. J Biol Chem 263:7792, 1988
167. Beebe DP, Miles LA, Plow EF: A linear amino acid sequence involved in the interaction of t-PA with its endothelial cell receptor. Blood 74:2034, 1989
168. Fukao H, Hagiya Y, Nonaka T, Okada K, Matsuo O: Analysis of binding protein for tissue-type plasminogen activator in human endothelial cells. Biochem Biophys Res Commun 187:956, 1992
169. Ramakrishnan V, Sinicropi DV, Dere R, Darbonne WC, Bechtol KB, Baker JB : Interaction of wild-type and catalyrically inactive mutant forms of tissue-type plasminogen activator with human umbilical vein endothelial cell monolayers. J Biol Chem 265:2755, 1990
170. Cheng X-F, Pohl G, Back O, Wallen P: Characterization of receptors interacting specially with the B-chain of tissue plasminogen activator on endothelial cells. Fibrinolysis 10:167, 1996
171. Hajjar KA, Hamel NM, Harpel PC, Nachman RL: Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest 80:1712, 1987
172. Hajjar KA, Hamel NM: Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J Biol Chem 265:2908, 1990
173. Weling TH, Huber TS, Messina LM, Stanley JC: Tissue plasminogen activator increases canine endothelial cell proliferation rate through a plasmin-independent, receptor-mediated mechanism. J Surg Res 66:36, 1996
174. Hajjar KA, Jacovina AT, Checko J: An endothelial cell receptor for plasminogen/tissue plasminogen activator. J Biol Chem 269:21191, 1994
175. Barnathan ES, Kuo A, Rosenfeld L, Kariko K, Leski M, Robbiati F, Nolli ML, Henkin J, Cines DB: Interaction of single chain urokinase type plasminogen activator with human endothelial cells. J Biol Chem 265:2865, 1990
176. Barnathan ES, Kuo A, Kariko K, Rosenfeld L, Murray SC, Behrendt N, Ronne E, Weiner D, Henkin J, Cines DB: Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and mRNA. Blood 76:1795, 1990
177. Wun TC, Schleuning W-D, Reich E: Isolation and characterization of urokinase from human plasma. J Biol Chem 257:3276, 1982
178. Manchanda N, Schwartz BS: Single chain urokinase. Augmentation of enzymatic activity upon binding to monocytes. J Biol Chem 266:14580, 1991
179. Schwartz BS: Differential inhibition of soluble and cell surface receptor bound scu-PA by plasminogen activator inhibitor. J Biol Chem 269:8319, 1994
180. Higazi AA-R, Mazar A, Wang J, Reilly R, Henkin J, Kniss D, Cines D: Single chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Blood 87:3545, 1996
181. Pepper MS, Sappino A-P, Stocklin R, Montesano R, Orci L, Vassalli J-D: Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 122:673, 1993
182. Bugge TH, Flick MJ, Danton MJS, Daugherty CC, Romer J, Dano K, Carmeliet P, Coden D, Degen JL: Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 93:5899, 1996
183. Miles LA, Levin EG, Plescia J, Collen D, Plow EF: Plasminogen receptors, urokinase receptors, and their modulation on human endothelial cells. Blood 72:628, 1988
184. Plow EF, Freaney DE, Plescia J, Miles LA: The plasminogen system and cell surfaces: Evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 103:2411, 1986
185. Ploplis VA, Carmeliet P, Vazirzadeh S, van Vlaenderen I, Moons L, Plow EF, Collen D: Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 92:2585, 1995
186. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF: A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 339:301, 1989
187. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A: The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med 1:74, 1995
188. Levin EG, Santell L: Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells. J Cell Biol 105:2543, 1987
189. Loskutoff DJ, Sawdey M, Mimuro J: Type 1 plasminogen activator inhibitor, in Coller BS (ed): Progress in Hemostasis and Thrombosis. Philadelphia, PA, Saunders, 1989, p 87
190. Sawdy MS, Loskutoff DJ: Regulation of murine type 1 plasminogen activator inhibitor gene in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β. J Clin Invest 88:1346, 1991
191. Astedt B, Hagerstrand I, Lecander I: Cellular localization in placenta of placental type plasminogen activator inhibitor. Thromb Haemost 56:63, 1986
192. Scarpati EM, Sadler JE: Regulation of endothelial cells coagulant properties. J Biol Chem 264:20705, 1989
193. Suzuki K, Nishioka J, Hashimoto S: Protein C inhibitor. Purification from human plasma and characterization. J Biol Chem 258:163, 1983
194. Geiger M, Prilinger U, Griffin JH, Binder BR: Urinary protein C inhibitor. Glycosaminoglycans synthesized by the epithelial cell line TC1-598 enhance its interaction with urokinase. J Biol Chem 266: 11851, 1991
195. Bajzar L, Morser J, Nesheim M: TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 271:16603, 1996
196. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, van Hinsbergh V, Sozzani S, Bussolino F, Poli V, Cilberto G, Mantovani A: Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6:315, 1997
197. Middleton J, Neil S, Wintle J, dark-Lewis I, Moore H, Lam C, Auer M, Hub E, Rot A: Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 91:385, 1997
198. Schafer AI: Vascular endothelium: In defense of blood fluidity. J Clin Invest 99:1143, 1997
199. Marcus AJ, Broekman MJ, Drosopoulos JHF, Islam N, Alyonycheva TN, Safier LB, Hajjar KA, Posnett DN, Shoenborn MA, Schoolet KA, Gayle RB, Maliszewski CR: The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 99:1351, 1997
200. Roth GJ: Platelets and blood vessels: The adhesion event. Immunol Today 13:100, 1992
201. Ruggeri Z, Ware J: von Willebrand factor. FASEB J 7:308, 1993
202. Dong J-f, Hyun W, Lopez JA: Aggregation of mammalian cells expressing the platelet glycoprotein (GP) Ib-IX complex and the requirement for tyrosine sulfation of GPIbα. Blood 86:4175, 1995
203. Lopez JA: The platelet glycoprotein Ib-IX complex. Blood Coagul Fibrinol 5:97, 1994
204. Savage B, Saldivar E, Ruggeri ZM: Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 84:289, 1996
205. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL: Platelets and shear stress. Blood 88:1525, 1996
206. Calvete JJ: Clues for understanding the structure and function of a prototypic human integrin: The platelet glycoprotein Hb/IIIa complex. Thromb Haemost 72:1, 1994
207. McEver RP, Moore KL, Cummings RD: Leukocyte trafficking mediated by selectin-carbohydrate interactions. J Biol Chem 270: 11025, 1995
208. Walcheck B, Moore KL, McEver RP, Kishimoto TK: Neutrophil-neutrophil interactions under hydrodynamic shear stress involve Lselectin and PSGL-1: A mechanism that amplifies initial leukocyte accumulation on P-selectin in vitro. J Clin Invest 98:1081, 1996
209. Buttrum SM, Hatton R, Nash GB: Selectin-mediated rolling of neutrophils on immobilized platelets. Blood 82:1165, 1993
210. Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C, Hsu Y-M, Sajer SA, Furie B: Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 359:848, 1992
211. Diacovo TG, Pun KD, Warnock RA, Springer TA, Von Andrian UH: Platelet-mediated lymphocyte delivery to high endothelial venules. Science 273:252, 1996
212. Hemmerich S, Leffler H, Rosen SD: Structure of the O-glycans in GlyCAM-1, an endothelial-derived ligand for L-selectin. J Biol Chem 270:12035, 1995
213. Wilkins PP, Moore KL, McEver RP, Cummings RD: Tyrosine sulfation of P-selectin glycoprotein ligand-1 is required for high affinity binding to P-selectin. J Biol Chem 270:22677, 1995
214. Wilkins PP, McEver RP, Cummings RD: Structures of the O-glycans on P-selectin glycoprotein ligand-1 from HL-60 cells. J Biol Chem 271:18732, 1996
215. McEver RP, Cummings RD: Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 100:485, 1997
216. Berlin C, Bargatz RF, Campbell JJ, Von Andrian UH, Szabo MC, Hasslen SR, Nelson RD, Berg EL, Erlandsen SL, Butcher EC: α4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell 80:413, 1995
217. Alon R, Kassner PD, Can MW, Finger EB, Hemler ME, Springer TA: The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. J Cell Biol 128:1243, 1995
218. DeGrendele HC, Estess P, Picker LJ, Siegelman MH: CD44 and its ligand hyaluronate mediate rolling under physiologic flow: A novel lymphocyte-endothelial cell primary adhesion pathway. J Exp Med 183:1119, 1996
219. Alon R, Hammer DA, Springer TA: Lifetime of the P-selectin: Carbohydrate bond and its response to tensile force in hydrodynamic flow. Nature 374:539, 1995
220. Finger EB, Puri KD, Alon R, Lawrence MB, Von Andrian UH, Springer TA: Adhesion through L-selectin requires a threshold hydrodynamic shear. Nature 379:266, 1996
221. Walcheck B, Kahn J, Fisher JM, Wang BB, Fisk RS, Payan DG, Feehan C, Betageri R, Darlak K, Spatola AF, Kishimoto TK: Neutrophil rolling altered by inhibition of L-selectin shedding in vitro. Nature 380:720, 1996
222. Patel KD, Mollert MU, McEver RP: P-selectin must extend a sufficient length from the plasma membrane to mediate rolling of neutrophils. J Cell Biol 131:1893, 1995
223. Weyrich AS, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA: Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-α secretion. J Clin Invest 95:2297, 1995
224. Springer TA: Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol 57:827, 1995
225. Languino LR, Plescia J, Duperray A, Brian AA, Plow EF, Geltosky JE, Altieri DC: Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell 73:1423, 1993
226. Muller WA, Weigl SA: Monocyte-selective transendothelial migration: Dissection of the binding and transmigration phases by an in vitro assay. J Exp Med 176:819, 1992
227. Dejana E, Corada M, Lampugnani MG: Endothelial cell-to-cell junctions. FASEB J 9:910, 1995
228. Johnson RC, Chapman SM, Dong ZM, Ordovas JM, Mayadas TN, Herz J, Hynes RO, Schaefer EJ, Wagner DD: Absence of P-selectin delays fatty streak formation in mice. J Clin Invest 99:1037, 1997
229. Anderson DC, Springer TA: Leukocyte adhesion deficiency: An inherited defect in the Mac-1, LFA-1, and p 150,95 glycoproteins. Annu Rev Med 38:175, 1987
230. Etzioni A, Frydman M, Pollack S, Avidor I, Phillips ML, Paulson JC, Gershoni-Baruch R: Brief report: Recurrent severe infections caused by a novel leukocyte adhesion deficiency. N Engl J Med 327:1789, 1992
231. Ley K, Tedder TF: Leukocyte interactions with vascular endothelium: New insights into selectin-mediated attachment and rolling. J Immunol 155:525, 1995
232. Frenette PS, Mayadas TN, Rayburn H, Hynes RO, Wagner DD: Susceptibility to infection and altered hematopoiesis and mice deficient in both P- and E-selectin. Cell 84:563, 1996
233. Bullard DC, Kunkel EJ, Kubo H, Hicks MJ, Lorenzo I, Doyle NA, Doerschuk CM, Ley K, Beaudet AL: Infectious susceptibility and severe deficiency of leukocyte rolling and recruitment in E-selectin and P-selectin double mutant mice. J Exp Med 183:2329, 1996
234. Frenette PS, Mayadas TN, Rayburn H, Hynes RO, Wagner DD: Susceptibility to infection and altered hematopoiesis in mice deficient in both P- and E-selectins. Cell 84:563, 1996
235. Maly P, Thall AD, Petryniak B, Rogers CE, Smith PL, Marks RM, Kelly RJ, Gersten KM, Cheng G, Saunders TL, Camper SA, Camphausen RT, Sullivan FX, Isogai Y, Hindsgaul O, von Andrian UH, Lowe JB: The a(l,3)fucosyltranferase Fuc-TVII controls leukocyte trafficking through an essential role in L-, E-, and P-selectin ligand biosynthesis. Cell 86:643, 1996
236. Kunkel EJ, Jung U, Bullard DC, Norman KE, Wolitzky BA, Vestweber D, Beaudet AL, Ley K: Absence of trauma-induced leukocyte rolling in mice deficient in both P-selectin and intercellular adhesion molecule 1. J Exp Med 183:571, 1996
237. Schmits R, Kundig TM, Baker IM, Shumaker G, Simard JJL, Duncan G, Wakeham A, Shaninian A, van der Heiden A, Bachman MF, Ohashi PS, Mak TW, Hickstein DD: LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor. J Exp Med 183:1415, 1996
238. Coxon A, Rieu P, Barkalow FJ, Askari S, Sharpe AH, von Andrian UH, Arnaout MA, Mayadas TN: A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: A homeostatic mechanism in inflammation. Immunity 5:653, 1996
239. Lu H, SMith CW, Perrard J, Bullard D, Tang L, Shappell SB, Entman ML, Beaudet AL, Ballantyne CM: LFA-1 is sufficient in mediating neutrophil emigration in MAC-1 deficient mice. J Clin Invest 99:1340, 1997
240. Arroyo AG, Yang JT, Rayburn H, Hynes RO: Differential requirements for α4 integrins during fetal and adult hematopoiesis. Cell 85:997, 1996
241. Pober JS, Orosz CG, Rose ML, Savage COS: Can graft endothelial cells initiate a host anti-graft immune response? Transplant 61:343, 1996
242. Murray AG, Libby P, Pober JS: Human vascular smooth muscle cells poorly costimulate and actively inhibit allogeneic CD4+ T cell proliferation in vitro. J Immunol 154:151, 1995
243. Marcelli-Berg FM, Hargreaves REG, Carmichael P, Dorling A, Lombardi G, Lechler RI: Major histocompatibility complex class II-expressing endothelial cells induce allospecific non-responsiveness in naive T cells. J Exp Med 183:1603, 1996
244. Murray AG, Khodadoust MM, Pober JS, Bothwell ALM: Porcine aortic endothelial cells strongly activate human T cells: Direct presentation of swine MHC antigens and effective costimulation by swine ligands for human CD2 and CD28. Immunity 1:57, 1994
245. Karman K, Hughes CCW, Schechner J, Fnaslow WC, Pober JS: CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 92:4342, 1995
246. Pober JS, Cotran RS: Cytokines and endothelial cell biology. Physiol Rev 70:427, 1990
247. Pober JS, Cotran RS: Overview: The role of endothelial cells in inflammation. Transplant 50:537, 1990
248. Austrup F, Vestweber D, Borges E, Lohning M, Grauer R, Herz V, Renz H, Hallmann R, Scheffold A, Rudbruch A, Hamann A: P- and E-slectin mediate recruitment of T helper 1 but not T helper 2 cells into inflammed tissues. Nature 385:81, 1997
249. Borges E, Tietz W, Steegmaier M, Moll T, Hallmann R, Hamann A, Vestweber D: P-selectin glycoprotein ligand-1 (PSGL-1 ) on T helper 1 but not T helper 2 cells binds to P-selectin and supports migration into inflammed skin. J Exp Med 185:573, 1997
250. Bradley JR, Pober JS: Prolonged cytokine exposure causes a dynamic redistribution of endothelial cell adhesion molecules to intercellular junctions. Lab Invest 75:463, 1996
251. Montesano R, Orci L, Vassalli P: Human endothelial cell cultures: Phenotypic modulation by leukocyte interleukins. J Cell Physiol 122:424, 1985
252. Stolpen AH, Guinan EC, Fiers W, Pober JS: Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am J Pathol 123:16, 1986
253. Jutte NHP, Knoof CJ, Heijse P, Balk AHMM, Mochtar B, Claas FHJ, Weimanr W: Human heart endothelial-cell-restricted allorecognition. Transplant 62:403, 1996
254. Damle NK, Doyle LV, Bender JR, Bradley EC: Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol 138:1779, 1987
255. H2 cytokine environment. Nat Med 3:196, 1997
256. Platt AF Jr, Eckman JR: The multidisciplinary management of pain in patients with sickle cell syndromes. J Am Acad Phys Assist 2:104, 1989
257. Howard RJ, Gilladoga AD: Molecular studies related to the pathogenesis of cerebral malaria. Blood 74:2603, 1989
258. Wautier JL, Wautier MP, Schmidt A-M, Anderson GM, Hori O, Zoukourian C, Capron L, Chappey O, Yan S-D, Brett J, Guillausseau P-J, Stern D: Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA 91:7742, 1994
259. Mozarelli A, Hofrichter J, Eaton WA: Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo. Science 237:500, 1987
260. Eaton WA, Hofrichter J, Ross PD: Delay time of gelation: A possible determinant of clinical severity of sickle cell disease. Blood 47:621, 1976
261. Hebbel RP, Yamada O, Moldow CF, Jacob HS, White JG, Eaton JW: Abnormal adherence of sickle erythrocytes to cultured vascular endothelium. Possible mechansism for microvascular occlusion. J Clin Invest 65:154, 1980
262. Wick TM, Moake JL, Udden MM, Eskin SG, Sean DA, McIntire LV: Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow. J Clin Invest 80:905, 1987
263. Kaul DK, Fabry ME, Nagel RL: Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: Pathophysiological implications. Proc Natl Acad Sci USA 86:3356, 1989
264. Wick TM, Eckman JR: Molecular basis of sickle cell-endothelial cell interactions. Curr Opin Hematol 3:118, 1996
265. Hebbel RP, Moldow CF, Steinberg MH: Modulation of erythrocyte-endothelial interactions and the vaso-occlusive severity of sickling disorders. Blood 58:947, 1981
266. Wautier JL, Wautier MP, Pintigny D, Galacteros F, Courillon A, Passa P, Caen JP: Factors involved in cell adhesion to vascular endothelium. Blood Cells 9:221, 1983
267. + sickle reticulocytes to endothelial cells. Blood 80:2634, 1992
268. Brittain HA, Eckman JR, Howard RJ, Wick TM: Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: A potential role for platelet activation in sickle cell vaso-occlusion. Blood 81:2137, 1993
269. 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood 82:3548, 1993
270. 1-integrin expression on sickle reticulocytes: Vascular cell adhesion molecule-dependent binding to endothelium. Blood 82:1891, 1993
271. Setty BNY, Stuart MJ: Vascular adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: Potential role in sickle cell disease. Blood 88:2311, 1996
272. Smolinski PA, Offermann MK, Eckman JR, Wick TM: Synthetic double stranded RNA increases sickle red blood cell adherence to endothelium via a VCAM-1/VLA-4 pathway. Blood 85:2945, 1995
273. 1 integrin receptors on sickle reticulocytes and fibronectin. Blood 88:4348, 1996
274. Natarajan M, Udden MM, McIntire LV: Adhesion of sickle red blood cells and damage to interleukin-1β stimulated endothelial cells under flow in vitro. Blood 87:4845, 1996
275. Styles LA, Lubin B, Vichinsky E, Lawrence S, Hua M, Test S, Kuypers F: Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 89:2554, 1997
276. Brittain HA, Eckman JR, Wick TM: Sickle etythrocytic adherence to large vessel and microvascular endothelium under physiologic flow is qualitatively different. J Lab Clin Med 19:538, 1992
277. Swerlick RA, Lee KH, Wick TM, Lawley TJ: Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. J Immunol 148:78, 1992
278. Smolinski PA, Eckman JR, Wick TM: Increased tenacity of sickle erythrocyte-endothelial adherence by involvement of multiple receptor-ligand interactions. Blood 86:298a, 1995 (abstr, suppl 1 )
279. Kaul DK, Fabry ME, Nagel RL: Vaso-occulusion by sickle cells: Evidence for selective trapping of dense cells. Blood 68:1162, 1986
280. Setty BNY, Chen D, Stuart MJ: Sickle red blood cells stimulate endothelial cell production of eicosanoids and diacyglycerol. J Lab Clin Med 128:313, 1996
281. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP: Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 337:1584, 1997
282. Ockenhouse CF, Tegodhi T, Maeno Y, Benjamin C, Ho M, Kan KE, Thway Y, Win K, Aikawa M, Lobb R: Human vascular endothelial cell adhesion receptors for Plasmodium falciparum-infected erythrocytes: Roles for endothelial leukocyte adhesion molecule 1 and vascular cell adhesion molecule 1. J Exp Med 176:1183, 1992
283. Cooke BM, Berendt AR, Craig AG, MacGergor J, Newbold CI, Nash GB: Rolling and stationary cytoadhesion of red blood cells parasitized by Plasmodium falciparum: Separate roles for ICAM-1, CD36 and thrombospondin. Br J Haematol 87:162, 1994
284. McCormick CJ, Craig A, Roberts D, Newbold CI, Berendt AR: Intercellular adhesion molecule-1 and CD36 synergize to mediate adherence of Plasmodium falciparum-infected erythrocytes to cultured human microvascular endothelial cells. J Clin Invest 100:2521, 1997
285. Elhassan IM, Hviid L, Satti G, Akerstrom B, Jakobsen PH, Jensen JB, Theander TG: Evidence of endothelial inflammation, T cell activation and T cell reallocation in uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 51:372, 1994
286. Jakobsen PH, Bate CAW, Taverne J, Playfair JHL: Malaria: Toxins, cytokines and disease. Parasite Immunol 17:223, 1995
287. Crandall I, Collins WE, Gysin J, Sherman IW: Synthetic peptides based on motifs present in human band 3 protein inhibit cytoadherence/sequestration of the malaria parasite Plasmodium falciparum. Proc Natl Acad Sci USA 90:4703, 1993
288. Crandall I, Sherman IW: Cytoadherence-related neoantigens on Plasmodium falciparum (human malaria)-infected erythrocytes result from the exposure of normally cryptic regions of the band 3 protein. Parasitology 108:257, 1994
289. Chaiyoroj S, Angkasekwinai P, Buranakiti A, Looareesuwan S, Rogerson SJ, Brown GV: Cytoadherence characteristics of Plasmodium falciparum isolates from Thailand: Evidence for chondroitin sulfate A as a cytoadherence receptor. Am J Trop Med Hyg 55:76, 1996
290. Wautier JL, Panton RC, Wautier MP, Pintigny D, Abadie E, Passa P, Caen JP: Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus and its relation to vascular complications. N Engl J Med 305:237, 1981
291. Ross R, Glomset JA: The pathogenesis of atherosclerosis (second of two parts). N Engl J Med 295:420, 1976
292. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801, 1993
293. McGorisk GM, Treasure CB: Endothelial dysfunction in coronary heart disease. Curr Opin Cardiol 11:341, 1996
294. Henry PD: Hyperlipidemic endothelial injury and angiogenesis. Basic Res Cardiol 1:107, 1994
295. Larrick JW, Wright SC: Hypertension-enhanced monocyte adhesion in experimental atherosclerosis. FASEB J 4:3215, 1990
296. Schmidt AM, Hori O, Brett J, Van SD, Wautier JL, Stern D: Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogensis of vascular lesions. Arterioscler Thromb 14:1521, 1994
297. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM: Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 92:1866, 1993
298. Gimbrone MA Jr: Vascular endothelium: An integrator of pathophysiologic stimuli in atherosclerosis. Am J Cardiol 75:67B, 1995
299. Davies P: Flow-mediated endothelial mechanotransduction. Physiol Rev 75:519, 1995
300. Malek AM, Izumo S: Control of endothelial cell gene expression by flow. J Biomechanics 28:1515, 1995
301. McLenachan JM, Vita J, Fish DR, Treasure CB, Cox DA, Ganz P, Selwyn AP: Early evidence of endothelial vasodilator dysfunction at coronary branch points. Circulation 82:1169, 1990
302. Ando J, Kamiya A: Flow-dependent regulation of gene expression in vascular endothelial cells. Heart J 37:19, 1996
303. Tsao PS, Buitrago R, Chan JR, Cooke JP: Fluid flow inhibits endothelial adhesiveness: Nitric oxide and transcriptional regulation of VCAM-1. Circulation 94:1682, 1996
304. Grabowski EF, Lam FP: Endothelial cell function, including tissue factor expression, under flow conditions. Thromb Haemost 74:123, 1995
305. Khachigian LM, Resnick N, Gimbrone MA Jr, Collins T: Nuclear factor KB interacts functionally with the platelet-derived growth factor B-chain shear-stress response element in vascular endothelial cells exposed to fluid shear stress. J Clin Invest 92:1706, 1993
306. Ohno M, Cooke JP, Dzau VJ, Gibbons GH: Fluid shear stress induces endothelial transforming growth factor beta-1 transcription and production. J Clin Invest 96:1169, 1995
307. Lan Q, Mercurius KO, Davies PF: Stimulation of transcription factors NpκV and APl in endothelial cells subjected to shear stress. Biochem Biophys Res Commun 201:950, 1994
308. Guba SC, Fink LM, Fonseca V: Hyperhomocysteinemia. An emerging and important risk factor for thromboembolic and cardiovascular disease. Am J Clin Pathol 105:709, 1996
309. Rees MM, Rodgers GM: Homocysteinemia: Association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 71:337, 1993
310. Mayer EL, Jacobsen DW, Robinson K: Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 27:517, 1996
311. Harpel PC, Zhang X, Borth W: Homocysteine and hemostasis: Pathogenetic mechanisms predisposing to thrombosis. J Nutrition 71:1285S, 1996
312. Starkebaum G, Harlan JM: Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 77:1370, 1993
313. Heinecke JW, Rosen H, Suzuki LA, Chait A: The role of sulfur-containing amino acids in Superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 262:10098, 1987
314. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J: Adverse vascular effects of homocytsteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91:308, 1993
315. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM: Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 13:1327, 1993
316. Rodgers GM, Kane WH: Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 77:1909, 1986
317. Hajjar KA: Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 91:2873, 1993
318. Lentz SR, Sadler JE: Inhibtion of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 88:1906, 1991
319. Nishinaga M, Ozawa T, Shimada K: Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 92:381, 1992
320. Wang J, Dudman NPD, Wilken DE: Effects of homocysteine and related compounds on prostacyclin production by cultured vascular endothelial cells. Thromb Haemost 6:1047, 1993
321. Tsai JC, Perella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME: Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 91:6369, 1994
322. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD: Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 98:24, 1996
323. Van Den Berg M, Boers GHJ, Franken DG, Blom HJ, van Kamp GJ, Jakobs C, Rauwerda JA, Kluft C, Stehouwert CDA: Hyperhomocysteinemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 25:176, 1995
324. Gryglewski RJ, Chlopicki S, Swies J, Niezabitowski P: Prostacyclin, nitric oxide, and atherosclerosis. Ann NY Acad Sci 748:194, 1995
325. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315:1046, 1986
326. Siegel G, Ruckborn K, Schnalke F, Muller J: Endothelial dysfunction in human atherosclerotic coronary arteries. Eur Heart J 1:99, 1993
327. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE: Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest 93:50, 1994
328. Tsurumi Y, Nagashima H, Ichikawa K, Sumiyoshi T, Hosoda S: Influence of plasma lipoprotein(a) levels on coronary vasomotor response to acetylcholine. J Am Coll Cardiol 26:1242, 1995
329. Steinberg HO, Chaker H, Learning R, Johnson A, Brechtel G, Baron AD: Obesity/insulin resistance is associated with endothelial dysfunction. J Clin Invest 97:2601, 1996
330. Celermajer DS, Sorensen K, Ryalls M, Robinson J, Thomas O, Leonard JV, Deanfield JE: Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 22:854, 1993
331. Woodman OL: Modulation of vasoconstriction by endothelium-derived nitric oxide: The influence of vascular disease. Clin Exp Pharmacol Physiol 22:585, 1995
332. Heistad DD, Baumbach GL, Faraci FM, Armstrong ML: Sick vessel syndrome: Vascular changes in hypertension and atherosclerosis. J Hum Hypertens 9:449, 1995
333. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE: Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 24:471, 1994
334. Celermajer DS, Sorensen KB, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE: Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 88:2149, 1993
335. Kingwell BA, Tran B, Cameron JD, Jennings GL, Dart AM: Enhanced vasodilation to acetylcholine in athletes is associated with lower plasma cholesterol. Am J Physiol 270:H2008, 1996
336. Fish RD, Nabel EG, Selwyn AP, Ludmer PL, Mudge GH, Kirshenbaum JM, Schoen FJ, Alexander RW, Ganz P: Responses of coronary arteries of cardiac transplant patients to acetylcholine. J Clin Invest 81:21, 1988
337. Reddy KG, Nair RN, Sheehan HM, Hodgson JM: Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 23:833, 1994
338. Buttery LD, Chester AH, Springall DR, Borland JA, Michel T, Yacoub MH, Polak JM: Atherogenic levels of low-density lipoprotein increase hydrogen peroxide generation in cultured human endothelial cells: Possible mechanism of heightened endocytosis. J Pathol 179:197, 1996
339. Holland JA, Ziegler LM, MEyer JW: Atherogenic levels of low-density lipoprotein increase hydrogen peroxide generation in cultured human endothelial cells: Possible mechanism of heightened endocytosis. J Cell Physiol 166:144, 1996
340. 2 does not contribute to impaired endothelium-dependent relaxation. Arterioscler Thromb 14:746, 1994
341. Cooke JP: Role of nitric oxide in progression and regression of atherosclerosis. West J Med 164:419, 1996
342. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP: L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 90:1248, 1992
343. Mathew V, Hasdai D, Lerman A: The role of endothelin in coronary atherosclerosis. Mayo Clin Proc 71:769, 1996
344. Sawamura T, Kume N, Aoyami T, Morlwaki H, Hoshikawa H, Alba Y, Tanaka R, Miwa S, Katsura Y, Kita T, Masaki T: An endothelial receptor for oxidized low-density lipoprotein. Nature 386:73, 1997
345. Boulanger CM, Tanner FC, Bea ML, Hahn AW, Werner A, Luscher TF: Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res 70:1191, 1992
346. Lerman A, Holmes DR Jr, Bell MR, Garratt KN, Nishimura RA, Burnett JC Jr: Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 94:2426, 1995
347. Haak T, Marz W, Jungmann E, Hausser S, Siekmeier R, Gross W, Usadel KH: Elevated endothelin levels in patients with hyperlipoproteinemia. Clin Invest 72:580, 1994
348. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 344:633, 1994
349. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332:4811, 1995
350. Hennig B, Diana JN, Toborek M, McClain CJ: Influence of nutrients and cytokines on endothelial cell metabolism. J Am Coll Nutr 13:224, 1994
351. Heitzer T, Just H, Munzel T: Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 94:6, 1996
352. Levine GN, Frei B, Koulouris SN, Gerhard MD, Kenaey JR Jr, Vita JA: Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 93:1107, 1996
353. Chobanian AV, Haudenschild CC, Nickerson C, Hope S: Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension 20:473, 1992
354. Overturf ML, Sybers HD, Smith SA: Captopril-induced hyperreninemia in cholesterol-fed rabbits. Res Commun Chem Pathol Pharmacol 47:229, 1985
355. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B: Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 90:2056, 1994
356. Stroes ESG, Koomans HA, deBruin TWA, Rabelink TJ: Vascular function in the forearm of hypercholesterolaemic patients on and off lipid-lowering medication. Lancet 346:467, 1995
357. Wada H, Mori Y, Kaneko T, Wakita Y, Nakase T, Minamikawa K, Ohiwa M, Tamaki S, Tanigawa M, Kayegama S, Deguchi K, Nakano T, Shirakawa S, Suzuki K: Elevated levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol 44:112, 1993
358. Hackman A, Abe Y, Insull W Jr, Pownall H, Smith L, Dunn K, Gotto AM Jr, Ballantyne CM: Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 93:1334, 1996
359. Morrow JD, Roberts LJ: The isoprostanes. Current knowledge and directions for future research. Biochem Pharm 51:1, 1996
360. Reilly M, Delanty N, Lawson JA, FitzGerald GA: Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 94:19, 1996
361. kipl regulatory checkpoint. J Clin Invest 99:2867, 1997
362. Ruderman A, Williamson N, Brownlee M: Glucose and diabetic vascular disease. FASEB J 6:2905, 1992
363. Browlee M, Cerami A, Viassara H: AGEs in tissues and the biochemical basis of diabetic complications. N Engl J Med 318:1315, 1989
364. Schmidt A-M, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M, Wang F, Pan Y-C, Tsang T, Stern D: Isolation and characterization of binding proteins for AGEs from lung tissue which are present on the endothelial cell surface. J Biol Chem 267:14987, 1992
365. Schmidt A-M, Hori O, Brett J, Van S-D, Wautier S-D, Stem D: Cellular receptors for AGEs: Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1521:1528, 1994
366. Khoury J, Thomas C, Loike J, Hickman S, Cao L, Silverstein S: Macrophages adhere to glucose-modified basement membrane via their scavenger receptors. J Biol Chem 269:10197, 1994
367. Lander HL, Tauras JM, Ogiste JS, Moss RA, Schmidt A-M: Activation of the receptor for advanced glycation endproducts trigger a MAP kinase pathway regulated by oxidant stress. J Biol Chem 272:17810, 1997
368. Schmidt A-M, Hori O, Chen J, Li J, Crandall J, Zhang J, Cao R, Van S-D,
369. Schmidt A-M, Crandall J, Cao R, Hori P, Lakatta E: Elevated plasma levels of vascular cell adhesion molecules-1 (VCAM-1) in diabetic patients with microalbuminuria: A marker of vascular dysfunction and progressive vascular disease. Br J Haematol 92:747, 1996
370. Solez K, Axelsen RA, Bendiktsson H, Burdick JF, Cohen AF, Colvin RB, Croker BP, Droz D, Dunnill MS, Halloran PF, Hayry P, Jennette JC, Keown PA, Marcussen N, Mihatsch MJ, Morozumi K, Myers ND, Nast CC, Olsen S, Racusen LC, Ramos EC, Rosen S, Sachs DH, Salomon DR, Sanfilippo F, Verani R, von WIllebrand E, Yamaguch Y: International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 44:411, 1993
371. Pober JS: Vascular endothelium in transplantation, in Tilney NC, Strom TB, Paul LC (eds): Transplantation Biology: Cellular and Molecular Aspects. Philadelphia, PA, Lipincott-Raven, 1996, p 127
372. Strehlau J, Pavlakis M, Lipman M, Shapiro M, Vascincellos L, Harmon W, Strom TB: Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA 94:695, 1997
373. Meehan SM, McClusky RT, Pascual M, Preffer FI, Anderson P, Schlossman SF, Colvin RB: Cytotoxicity and apoptosis in human renal allograft: Identification, distribution and quantitation of cells with a cytotokic granule protein GMP 17 (TIA-1) and cells with fragmented nuclear DNA. Lab Invest 76:639, 1997
374. Jutte NHPM, Knoop CJ, Heijse P, Balk AHMM, Mochtar B, Claas FHJ, Weimar W: Human heart endothelial cell-restricted allorecognition. Transplant 62:403, 1996
375. Dvorak HF, Mihm MC Jr, Dvorak AM, Barnes BA, Manseau EJ, Galli SJ: Rejection of first-set skin allografts in man. The microvasculature is the critical target of the immune response. J Exp Med 150:322, 1981
376. Gao S-Z, Alderman EL, Schroeder JS, Silverman JF, Hunt SA: Accelerated coronary vascular disease in the heart transplant patient: Coronary angiographic findings. J Am Coll Cardiol 12:334, 1988
377. Salomon RN, Hughes CCW, Schoen FJ, Payne DD, Pober JS, Libby P: Human coronary transplantation-associated arteriosclerosis: evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol 138:791, 1991
378. Hurban RH, Beschorner WE, Baumgartner WA, Augustine SM, Ren H, Reitz BA, Hutchins GM: Accelerated arteriosclerosis in heart transplant recipients is associated with a T-lymphocyte-mediated endothelialitis. Am J Pathol 137:871, 1990
379. Dong C, Wilson JE, Winters GL, McManus BM: Human transplant coronary artery disease: Pathologic evidence for fasmediated cytotoxicity in allograft arteriopathy. Lab Invest 74:921, 1996
380. d'Apice AJ, Pearse MJ: Xenotransplantation, in Tilney NC, Strom TB, Paul LC (eds): Transplanation Biology: Cellular and Molecular Aspects. Philadelphia, PA, Lippincott-Raven, 1996, p 701
381. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IFC: Anti-pig IgM antibodies in human serum react predominantly with Gal (α1-3) Gal epitopes. Proc Natl Acad Sci USA 90:11391, 1993
382. Rooney IA, Liszeuski MK, Atkinson JP: Using membrane band complement regulatory proteins to inhibit rejection. Xeno 1:29, 1993
383. Murray AG, Khodadoust MM, Pober JS, Bothwell ALM: Porcine aortic endothelial cells strongly activate T cells: Direct presentation of swine MHC antigens and effective costimulation by swine ligands for human CD2 and CD28. Immunity 1:57, 1994
384. Blakely ML, Van Der Werf WJ, Berndly MC, Dalmasso AP, Bach FH, Hancock WW: Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplant 58:1059, 1994
385. Sultan P, Murray AG, McNiff JM, Lorber MI, Askenase PW, Bothwell ALM, Pober JS: Pig but not human interferon-γ initiated human endothelial cell-mediated rejection of pig tissue in vivo. Proc Natl Acad Sci USA 94:8767, 1997
386. McCrae KR, Cines DB: Immunologic properties of antibodies to endothelial cells: Relationship to antiphospholipid antibodies, in Cervera R, Khamashta MA, Hughes GRV (eds): Antibodies to Endothelial Cells and Vascular Damage. Boca Raton, FL, CRC, 1994, p 47
387. Cines DB, Lyss AP, Reeber MJ, Bina M, DeHoratius R: Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus. J Clin Invest 73:611, 1984
388. McCrae KR, DeMichele A, Samuels P, Roth D, Kuo A, Meng Q-H, Rauch J, Cines DB: Detection of endothelial cell-reactive immunoglobulin in patients with anti-phospholipid antibodies. Br J Haematol 79:595, 1991
389. Cines DB: Disorders associated with antibodies to endothelial cells. Rev Infect Dis 11:705, 1989
390. Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, Silverstein RL: Activaton of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 96:2211, 1995
391. Angles-Cano E, Sultan Y, Clauvel JP: Predisposing factors to thrombosis in systemic lupus erythematosus. Possible relation to endothelial cell damage. J Lab Clin Med 94:312, 1979
392. Arepally G, Cines DB: Heparin-associated antibodies, in Shoenfeld Y, Peter J (eds): Autoantibodies. Amsterdam, The Netherlands, Elsevier, 1996, p 343
393. McCrae KR, Cines DB: Drug-induced thrombocytopenias, in Loscalzo J, Schafer AI (eds): Thrombosis and Hemorrhage. Boston, MA, Blackwell Scientific, 1994, p 545
394. Amiral J, Bridey F, Dreyfus M, Vissac AM, Fressinaud E, Wolf M, Meyer D: Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 68:95, 1992
395. Visentin GP, Ford SE, Scott JP, Aster RH: Antibodies from patients with heparin induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 93:81, 1994
396. Cines DB, Tomaski A, Tannenbaum S: Immune endothelial cell injury in heparin-associated thrombocytopenia. N Engl J Med 316:581, 1987
397. Mayet W-J, Csernok E, Szymkowiak C, Gross WL, Meye zum Buschenfelde K-H: Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener's granulomatosis. Blood 82:1221, 1993
398. Damianovich M, Gilburd B, George J, Del Papa N, Afek A, Goldberg I, Kopolovic Y, Roth D, Barkai G, Meroni P-L, Shoenfeld Y: Pathogenic role of anti-endothelial cell antibodies in vasculitis. An idiotypic experimental model. J Immunol 156:4946, 1996
399. Savage COS, Pottinger BE, Gaskin G, Lockwood CM, Pusey CD, Pearson JD: Vascular damage in Wegener's granulomatosis and microscopic polyarteritis: Presence of anti-endothelial cell antibodies and their relation to anti-neutrophil cytoplasm antibodies. Clin Exp Immunol 85:14, 1991
400. Leung DYM, Havens PL, Moake JL, Kim M, Pober JS: Lytic anti-endothelial cell antibodies in haemolytic-uremic syndrome. Lancet 2:183, 1988
401. Carvalho D, Savage COS, Black CM, Pearson JD: IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cell in vitro. J Clin Invest 97:111, 1996
402. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G: Endothelial cell apoptosis is a primary pathogenic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98:785, 1996
403. Schett G, Xu Q, Amberger A, van der Zee R, Recheis H, Willeit J, Wick G: Autoantibodies against heat shock protein 60 mediates endothelial cytotoxicity. J Clin Invest 96:2569, 1995
404. Leung DYM, Collins T, Lapierre LA, Geha RS, Pober JS: Immunoglobulin M antibodies present in the acute phase of Kawaski syndrome lyse cultured endothelial cells stimulated by gamma interferon. J Clin Invest 77:1428, 1986
405. Cervera R, Navarro M, Lopez-Soto A, Cid M-C, Font J, Esparza J, Reverter JC, Monteagudo J, Ingelmo M, Urbano-Marquez A: Antibodies to endothelial cells in Behcet's disease: Cell-binding heterogeneity and association with disease activity. Ann Rheumatol Dis 53:265, 1994
406. Brasile L, Zerbe T, Rabin B, Clarke J, Abrams A, Cerilli J: Identification of the antibody to vascular endothelial cells in patients undergoing cardiac transplantation. Transplant 40:672, 1985
407. Boehme MWJ, Schmitt WH, Youinou P, Stremmel WR, Gross WL: Clinical relevance of elevated serum thrombomodulin and soluble E-selectin with Wegerner's granulomatosis and other systemic vasculitides. Am J Med 101:387, 1996
408. Favaloro EJ: Differential expression of surface antigens on activated endothelium. Immunol Cell Biol 71:571, 1993
409. Cotran RS, Gimbrone MA Jr, Bevilacqua MP, Mendrick DL, Pober JS: Induction and detection of a human endothelial activation antigen in vivo. J Exp Med 164:661, 1986
410. Groger MG, Sarmay E, Fiebirger E, Wolff K, Petzelbauer P: Dermal microvascular endothelial cells express CD32 receptors in vivo and in vitro. J Immunol 156:1549, 1996
411. Cines DB, Lyss AP, Bina M, COrkey R, Kefalides NA, Friedman HM: Herpes simplex virus enhances the expression of receptors for C3 and the Fc portion of immunoglobulin G and human endothelial cells. J Clin Invest 69:123, 1982
412. Johnson E, Hetland G: Human umbilical vein endothelial cells synthesize functional C3, C5, C6, C8 and C9 in vitro. Scand J Immunol 33:667, 1991
413. Brooimanns RA, Van der Ark AAJ, Buurman WA, van Es LA, Daha MR: Differential regulation of complement factor H and C3 production in human umbilical vein endothelial cells by IFN-γ and IL-1. J Immunol 144:3835, 1990
414. Schmaier AH, Murray SC, Heda GH, Farber A, Kuo A, McCrae K, Cines DB: Synthesis and expression of C1 inhibitor by human umbilical vein endothelial cells. J Biol Chem 264:18173, 1989
415. Brooimans RA, Van der Ark AAJ, Tomita M, van Es LA, Daha MR: CD59 expressed by human endothelial cells functions as a protective molecule against complement-mediated lysis. Eur J Immunol 22:791, 1992
416. Venneker GT, van den Hoogen FHJ, Boerbooms AMT, Bos JD, Asghar SS: Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage. Lab Invest 70:830, 1994
417. Asch AS, Kinoshita T, Jaffe EA, Nussenzweig V: Decay-accelerating factor is present on cultured human umbilical vein endothelial cells. J Exp Med 163:221, 1986
418. McNearney T, Ballard L, Seya T, Atkinson JP: Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells. J Clin Invest 84:538, 1989
419. Nose M, Katoh M, Okada N, Kyogoku M, Okada H: Tissue distribution of HRF-20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. Immunology 70:145, 1990
420. Daha MR, Miltenburg AMM, Hiemstra PS, Klar-Mohamad N, van Es LA, Van Hinsburg VWM: The complement subcomponent C1q mediated binding of immune complexes and aggregates to endothelial cells in vitro. Eur J Immunol 18:783, 1988
421. Lozada C, Levin RI, Huie M, Hirschhorn R, Naime D, Whitlow M, Recht PA, Golden B, Cronstein BN: Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selecton and intercellular and vascular adhesion molecules 1. Proc Natl Acad Sci USA 92:8378, 1995
422. Foreman KE, Vaporciyan BK, Bonish ML, Jones KJ, Glovsky MM, Eddy SM, Ward PA: C5a induced expression of P-selectin in endothelial cells. J Clin Invest 94:1147, 1994
423. Kilgore KS, Shen JP, Miller BF, Ward P, Warren JS: Enhancement by the complement membrane attack complex of tumor necrosis factor-α-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol 155:1434, 1995
424. Kilgore KS, Schmid E, Shanley TP, Flory CM, Maheswari V, Tramontini NL, Cohen H, Ward PA, Friedl HP, Warren JS: Sublytic concentrations of the membrane attack complex of complement induce endothelial cell interleukin-8 and monocyte chemoattractamt protein-1 through nuclear factor-κB activation. Am J Pathol 150:2019, 1997
425. Saadi S, Holznecht RA, Patte CP, Stern DM, Platt JL: Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 182:1807, 1995
426. Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A: The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 185:1619, 1997
427. Hattori R, Hamilton KK, McEver RP, Sims PJ: Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 264:9053, 1989
428. Hamilton KK. Hattori R, Esmon CT, Sims PJ: Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 265:3809, 1990
429. 2 formation in cultured endothelial cells. Am J Physiol 253:C13, 1987
430. Christiansen VJ, Sims PJ, Hamilton KK: Complement C5b-9 increases plasminogen binding and activation on human endothelial cells. Arterioscler Thromb Vasc Biol 17:164, 1997
431. Moake JL: Haemolytic-uraemic syndrome: Basic science. Lancet 343:393, 1994
432. Heild GH: Haemolytic-uremic syndrome in practice. Lancet 343:398, 1994
433. Forsyth KD, Simpson AC, Fitzpatrick MM, Barratt TM, Levinsky RJ: Neutrophil-mediated endothelial cell injury in haemolytic uraemic syndrome. Lancet 2:411, 1989
434. Morigi M, Micheletti G, Figliuzzi M, Imberti B, Karmali MA, Remuzzi A, Remuzzi G, Zoja C: Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. Blood 86:4553, 1995
435. van Setten PA, Monnens LAH, Verstrate RGG, van den Heuvel LPWJ, Van Hinsbergh VWM: Effects of verotoxin-1 on nonadherent monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood 88:174, 1996
436. Harel Y, Suva M, Weinberg A, Cleary TB, Beutler B: A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. J Clin Invest 92:2110, 1993
437. Keusch GT, Acheson DWK, Aaldering L, Erban J, Jacewicz MS: Comparison of the effects of Shiga-like toxin 1 on cytokine- and butyrate-treated human umbilical and saphenous vein endothelial cells. J Infect Dis 173:1164, 1996
438. Kaye SA, Obrig TG: Effect of TNF-α, Shiga toxin and calcium ionophore on Weibel-Palade body content of endothelial cells: Possible implications for the hemolytic uremic syndrome. Thromb Res 79:415, 1995
439. Bergstein JM, Riley M, Bang NU: Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome. N Engl J Med 327:755, 1992
440. Moake JL, Byrnes JJ: Thrombotic microangiopathies associated with drugs and bone marrow transplantation. Hematol Oncol Clin North Am 10:485, 1996
441. Zoja C, Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G: Cyclosporin-induced endothelial cell injury. Lab Invest 56:455, 1986
442. Gottschall JL, Neahring B, McFarland JG, Wu G-G, Weitekamp LA, Aster RH: Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: Clinical and serological findings in nine patients and review of the literature. Am J Hematol 47:283, 1994
443. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D: Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307:1432, 1982
444. Wada H, Ohiwa M, Kaneko T, Tamaki S, Tanigawa M, Shirakawa S, Koyama M, Hayashi T, Suzuki K: Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. Am J Hematol 39:20, 1992
445. Glas-Greenwalt P, Hall JM, Panke TW, Kant KS, Allen CM, Pollak VE: Fibrinolysis in health and disease: Abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura. J Lab Clin Med 108:415, 1986
446. Katayama M, Handoa M, Araki Y, Ambo H, Kawal Y, Watanabe K, Ikeda Y: Soluble P-selectin is present in normal circulation and its plasma level is elevated in patients with thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome. Br J Haematol 84:702, 1993
447. Wu K, Hall ER, Rosai EC, Papp AC: Serum prostacyclin binding defects in thrombotic thrombocytopenic purpura. J Clin Invest 75:168, 1985
448. Kobayashi M, Wada H, Wakita Y, Shimura M, Nakase T, Hiyoyama K, Nagaya S, Minami N, Nakano T, Shiku H: Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Am J Hematol 73:10, 1995
449. Khong TY, De Wolf F, Robertson WB, Brosens I: Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and by small for gestational age infants. Am J Obstetr Gynecol 157:360, 1987
450. Khong TY, Sawyer IH, Heryet AR: An immunohistologic study of endothelialization of uteroplacental vessels in human pregnancy-Evidence that the endothelium is focally disrupted by trophoblast in preeclampsia. Am J Obstetr Gynecol 167:751, 1992
451. Ferris TF: Preeclampsia and postpartum renal failure: Examples of pregnancy-induced microangiopathy. Am J Med 99:343, 1995
452. Fitzgerald DJ, Entmann SSW, Mulloy K, Fitzgerald GA: Decreased prostacyclin biosynthesis preceding the clinical manifestations of pregnancy induced hypertension. Circulation 75:956, 1987
453. Taylor RN, Varma M, Teng NN, Roberts JM: Women with pre-eclampsia have higher plasma endothelin levels than women with normal pregnancy. J Clin Endocrinol Metabol 71:1675, 1990
454. + cellular fibronectin precede the clinical signs of preeclampsia. Am J Obstetr Gynecol 162:358, 1990
455. Friedman SA, Schiff E, Emeris JJ, Dekker GA, Sibai BM: Biochemical corroboration of endothelial involvement in severe pre-eclampsia. Am J Obstetr Gynecol 172:202, 1995
456. Redman CWG, Beilin LJ, Denson DWE, Bolton FG, Stirrat GM: Factor VIII consumption in pre-eclampsia. Lancet 2:1249, 1977
457. Rogers GM, Taylor RN, Roberts JM: Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells. Am J Obstetr Gynecol 159:906, 1988
458. Tsukimori K, Maeda H, Shingu M, Koyanagi T, Nounaga M, Nakano H: The possible role of endothelial cells in hypertensive disorders during pregnancy. Obstetr Gynecol 80:229, 1992
459. Endresen MJ, Tosti E, Lorentzen B, Henricksen T: Sera of preeclamptic women are not cytotoxic to endothelial cells in culture. Am J Obstetr Gynecol 172:196, 1995
460. Zammit VC, Whitworth JA, Brown MA: Preeclampsia: The effects of serum on endothelial cell prostacyclin, endothelin and cell membrane integrity. Am J Obstetr Gynecol 174:737, 1996
461. Smarason AK, Sargent IL, Redmna CWG: Endothelial cell proliferation is suppressed by plasma but not by serum from women with preeclampsia. Am J Obstetr Gynecol 174:787, 1996
462. Taylor RN, Casal DC, Jones LA, Varma M, Martin JN Jr, Roberts JM: Selective effects of preeclamptic sera on human endothelial cell procoagulant protein expression. Am J Obstetr Gynecol 165:1705, 1991
463. Lorentzen B, Endresen MJ, Hovig T, Haug E, Henriksen T: Sera from preeclamptic women increase the content of triglycerides and reduce the release of prostacyclin in cultured endothelial cells. Thromb Res 63:363, 1991
464. Roberts JM, Edep ME, Goldfein A, Taylor RN: Sera from preeclamptic women specifically activate human umbilical vein endothelial cells in vitro: Morphologic and biochemical evidence. Am J Reprod Immunol 27:101, 1992
465. Gallery EDM, Rowe J, Campbell S, Hawkins T: Effect of serum on secretion of prostacyclin and endothelin-1 by decidual endothelial cells from normal and preeclamptic pregnancies. Am J Obstetr Gynecol 173:918, 1995
466. Poranen A-K, Ekblad U, Uotila P, Ahotupa M: Lipid peroxidation and antioxidants in normal and pre-eclamptic pregnancies. Placenta 17:401, 1996
467. Ness RB, Roberts JR: Heterogenous causes constituting the single syndrome of preeclampsia: A hypothesis and its implications. Am J Obstetr Gynecol 175:1365, 1996